These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29959088)

  • 21. The processing of nanoparticles containing protein for suspension in hydrofluoroalkane propellants.
    Nyambura BK; Kellaway IW; Taylor KM
    Int J Pharm; 2009 May; 372(1-2):140-6. PubMed ID: 19429273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Swellable hydrogel particles for controlled release pulmonary administration using propellant-driven metered dose inhalers.
    Selvam P; El-Sherbiny IM; Smyth HD
    J Aerosol Med Pulm Drug Deliv; 2011 Feb; 24(1):25-34. PubMed ID: 20961166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs.
    Kunka R; Andrews S; Pimazzoni M; Callejas S; Ziviani L; Squassante L; Daley-Yates PT
    Respir Med; 2000 Jun; 94 Suppl B():S10-6. PubMed ID: 10919680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Solvation in hydrofluoroalkanes: How can ethanol help?
    Conti DS; Grashik J; Yang L; Wu L; da Rocha SR
    J Pharm Pharmacol; 2012 Sep; 64(9):1236-44. PubMed ID: 22881436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Formulation and evaluation of novel reverse microemulsions containing salmon calcitonin in hydrofluoroalkane propellants.
    Shan Z; Tan Y; Qin L; Li G; Pan X; Wang Z; Yu X; Wang Q; Wu C
    Int J Pharm; 2014 May; 466(1-2):390-9. PubMed ID: 24657140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New analytical techniques to facilitate preformulation screening in propellant systems.
    Mogalian E; Kuehl PJ; Myrdal PB
    Int J Pharm; 2007 Aug; 340(1-2):223-9. PubMed ID: 17498897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HPFP, a model propellant for pMDIs.
    Rogueda PG
    Drug Dev Ind Pharm; 2003 Jan; 29(1):39-49. PubMed ID: 12602491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ester group: how hydrofluoroalkane-philic is it?
    Peguin RP; Wu L; da Rocha SR
    Langmuir; 2007 Jul; 23(16):8291-4. PubMed ID: 17602576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Templated open flocs of anisotropic particles for pulmonary delivery with pressurized metered dose inhalers.
    Tam JM; Engstrom JD; Ferrer D; Williams RO; Johnston KP
    J Pharm Sci; 2010 Jul; 99(7):3150-65. PubMed ID: 20187139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmaceutical transition to non-CFC pressurized metered dose inhalers.
    Cripps A; Riebe M; Schulze M; Woodhouse R
    Respir Med; 2000 Jun; 94 Suppl B():S3-9. PubMed ID: 10919679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and pharmaceutical applications of a low-flow-rate single-nozzle impactor.
    Wang H; Bhambri P; Ivey J; Vehring R
    Int J Pharm; 2017 Nov; 533(1):14-25. PubMed ID: 28939463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of expansion chamber geometry on atomization and spray dispersion characters of a flashing mixture containing inerts. Part II: High speed imaging measurements.
    Ju D; Shrimpton J; Bowdrey M; Hearn A
    Int J Pharm; 2012 Aug; 432(1-2):32-41. PubMed ID: 22579579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Understanding solvation in hydrofluoroalkanes: ab initio calculations and chemical force microscopy.
    Wu L; Peguin RP; da Rocha SR
    J Phys Chem B; 2007 Jul; 111(28):8096-104. PubMed ID: 17580855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group.
    Ayres JG; Millar AB; Sykes AP
    Respir Med; 2000 Jun; 94 Suppl B():S42-50. PubMed ID: 10919685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group.
    Tonnel AB; Bons J; Legendre M; Prud'Homme A; Bugnas B; Evano-Celli I; Stuart AM
    Respir Med; 2000 Jun; 94 Suppl B():S29-34. PubMed ID: 10919683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic exposure and urinary cortisol effects of fluticasone propionate formulated with hydrofluoroalkane in 4- to 11-year-olds with asthma.
    Kim KT; Milgrom H; Yoon YK; Levy AL; Matz P; Welch MJ; Cahn A; Collins DA; Kathman S; Mehta R; Su SF; Kunka RL
    J Clin Pharmacol; 2008 Jan; 48(1):108-16. PubMed ID: 18094223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of surfactant effect on aggregates in model aerosol propellent suspensions.
    Bower C; Washington C; Purewal TS
    J Pharm Pharmacol; 1996 Apr; 48(4):337-41. PubMed ID: 8794979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Crosslinked chitosan nanoparticle formulations for delivery from pressurized metered dose inhalers.
    Sharma K; Somavarapu S; Colombani A; Govind N; Taylor KM
    Eur J Pharm Biopharm; 2012 May; 81(1):74-81. PubMed ID: 22245573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. International study group.
    Perruchoud AP; Lundback B; Yigla M; Sykes AP
    Respir Med; 2000 Jun; 94 Suppl B():S35-41. PubMed ID: 10919684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology.
    Taylor G; Warren S; Dwivedi S; Sommerville M; Mello L; Orevillo C; Maes A; Martin UJ; Usmani OS
    Eur J Pharm Sci; 2018 Jan; 111():450-457. PubMed ID: 29055732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.